MannKind Corp

Most Recent

  • uploads///Part  chart
    Company & Industry Overviews

    Pharma Stocks Show a Positive Trend

    The upward trend in the pharmaceutical sector for the week ending July 17, 2015, was not caused by the oversold or overbought condition.

    By Peter Neil
  • uploads///AdobeStock_
    Personal Finance

    What Are Penny Stocks, and Can They Make You Money?

    Newcomers to the stock market often dream of fast profits but don’t have large investing accounts. Then they hear about this thing called “penny stocks.”

    By David Moadel
  • uploads///Graph
    Company & Industry Overviews

    Analysts Give Positive Recommendations to MannKind in March

    Wall Street analysts expect upside potential of 75.00% for MannKind (MNKD) based on the company’s closing price on March 26.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    MNKD or AKBA: Which Is Expected to Report Faster Revenue Growth?

    On December 13, 2018, Akebia Therapeutics issued a press release announcing the completion of its merger with Keryx Biopharmaceuticals.

    By Margaret Patrick
  • uploads///dna _
    Company & Industry Overviews

    What Analysts Are Recommending for MannKind and Akebia in March

    On March 12, MannKind Corporation (MNKD) closed at $2.09, 8.29% higher than its previous closing price.

    By Margaret Patrick
  • uploads///medical _
    Company & Industry Overviews

    United Therapeutics Enters into a Collaboration with MannKind

    United Therapeutics (UTHR) and MannKind Corp. entered into a global agreement to develop and commercialize a pulmonary hypertension product.

    By Daniel Collins
  • uploads///Modern Insulin
    Company & Industry Overviews

    How Did Novo Nordisk’s Modern Insulin Segment Perform in 3Q17?

    In 3Q17, Novo Nordisk’s (NVO) NovoRapid reported revenues of 5.0 billion Danish krone (or DKK), which reflected ~9% growth on year-over-year (or YoY) basis.

    By Daniel Collins
  • uploads///Part  Graph
    Company & Industry Overviews

    IBB Returns to Positive: How Did Its Holdings Perform?

    The iShares NASDAQ Biotechnology ETF followed the market trend and gained 1.1% after a five-day losing streak, a positive beginning for the month of May.

    By Peter Neil
  • uploads///Graph Part  Nov
    Company & Industry Overviews

    XBI Tops Biotech ETF’s for the Week Ended November 27

    Sarepta Therapeutics closed at $37.4 and was trading 15.2% above the 100-day moving average price of $32.5. It has a weight of 0.8% in XBI.

    By Peter Neil
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.